Drug Withdrawals and Recalls: Why Medications Get Removed from the Market

Every year, dozens of medications disappear from pharmacy shelves-not because they’re outdated, but because they’re dangerous. Or worse, because they never worked at all. The public rarely hears about these withdrawals until someone they know gets hurt. But behind every recall is a complex, often slow-moving system designed to protect patients. And for years, that system failed too many people.

How a Drug Gets Approved-And Why It Might Be Removed

The FDA doesn’t approve drugs because they’re safe. It approves them because the benefits outweigh the risks. That’s the rule. But for some drugs, especially those approved under the accelerated approval pathway, that balance is based on hope, not proof. These drugs are fast-tracked for serious conditions like cancer or rare diseases, where waiting for full clinical data could mean death. So the FDA lets them go to market based on early signals-like tumor shrinkage or a lab marker-that suggest they might help.

But here’s the problem: those early signals don’t always mean real benefit. In fact, a 2022 study in JAMA Internal Medicine found that nearly 13% of drugs approved under this pathway were later withdrawn because they didn’t actually improve survival or quality of life. That’s not a glitch. It’s a design flaw.

Take Makena, a drug approved in 2011 to prevent preterm birth. It was based on a small study showing a slight drop in early labor. But years later, a large, rigorous trial showed it did nothing. Still, the FDA waited over a decade to pull it. By then, around 150,000 women had been prescribed it. That’s not just a delay-it’s a failure.

The Old System: Years of Waiting, Patients Left in the Dark

Before 2023, the FDA had no real timeline for withdrawing drugs. Once a sponsor failed to prove a drug worked, the agency could sit on the evidence for years. The average time to withdraw a drug after evidence of ineffectiveness was 46 months-almost four years. Meanwhile, patients kept getting prescriptions.

Oncology drugs were the worst offenders. One study from Penn LDI found that 26% of all accelerated approval cancer drugs were eventually pulled. In small cell lung cancer, 41% of patients treated with these drugs got them even after they were proven useless. Doctors didn’t know they were prescribing a dead end. Pharmacies didn’t know to stop filling them. And patients? They had no idea.

The system was opaque. The FDA didn’t always communicate clearly. A drug could be “withdrawn from sale” because the manufacturer stopped shipping it-but not because the FDA ordered it. Or it could be pulled for safety reasons, but only after dozens of adverse events piled up. There was no urgency. No accountability. Just paperwork.

The 2023 Change: A New Law, Faster Action

Everything changed with the Consolidated Appropriations Act of 2023. For the first time, the FDA got real power to move quickly. Now, if a drug approved under accelerated approval fails its confirmatory trial-or if the company doesn’t even try to complete it-the agency can act in months, not years.

The law sets clear triggers:

• The sponsor fails to conduct required post-approval studies
• The studies don’t verify the drug’s benefit
• Independent data proves it’s unsafe or ineffective
• The company spreads false claims about the drug

And the process? It’s structured. The FDA must notify the company within 30 days. The company gets a meeting with FDA leadership. There’s a public comment period. And the final decision? It must come within 180 days. No more dragging things out.

The first drug pulled under this new rule? An ALS treatment, withdrawn in August 2023 after confirmatory trials showed no benefit. It took less than six months from evidence to removal. That’s progress.

Who’s Affected When a Drug Is Pulled?

It’s not just patients. Everyone in the system feels the ripple.

Doctors have to switch treatments on the fly. One oncology practice reported it took an average of 72 hours just to find alternatives for patients on a withdrawn drug. Pharmacists scramble to update systems. Insurance companies deny claims for drugs that are no longer approved. And patients? They’re left wondering: Was I used as a test subject?

One metastatic breast cancer patient wrote on a patient forum in 2022: “I was on [withdrawn drug] for 18 months. My oncologist said it was standard. Now we know it didn’t help.”

That’s not rare. A 2023 Reddit thread on r/oncology had 142 comments. 87% of respondents said they worried they’d been prescribed a drug later pulled for being ineffective. The fear isn’t irrational. It’s based on history.

Why Some Drugs Get Withdrawn-and Others Don’t

Not all withdrawals are the same. About 60% are due to safety issues-unforeseen side effects, organ damage, or death. The rest? Mostly because they don’t work. A small number are pulled for marketing fraud or manufacturing problems.

But here’s the kicker: drugs approved traditionally-those with full clinical data before approval-are rarely pulled. The accelerated approval pathway is the problem zone. That’s where the risk is highest, and where oversight was weakest.

The FDA’s own data shows that 40% of all accelerated approvals go to oncology drugs. That’s 80 drugs as of 2023. And of those, about 1 in 4 ended up being pulled. That’s a huge number of patients exposed to treatments with no proven benefit.

What’s Still Broken

The 2023 law is a major step forward. But it’s not perfect.

First, it only applies to drugs approved after the law passed. That means Makena, and dozens of others approved before 2023, are stuck in the old system. The FDA still hasn’t acted on many of them.

Second, the agency still doesn’t always communicate clearly. A 2023 FDA audit found only 42% of withdrawal notices included clear timelines for doctors and patients. That leaves too much room for confusion.

Third, the FDA still relies heavily on sponsor-submitted data. Even with the new rules, it’s the drugmakers who run the confirmatory trials. And they have a financial incentive to delay bad news.

Real progress will come when the FDA starts using real-world data-like prescriptions filled, hospital admissions, or patient outcomes tracked through electronic records-to monitor drugs after approval. A pilot program launched in January 2024 using data from Flatiron Health is a start. But it’s still small.

What You Need to Know If You’re Taking a New Drug

If you’re prescribed a new drug for cancer, a rare disease, or another serious condition, ask these questions:

• Was this approved under accelerated approval?
• Has the confirmatory trial been completed?
• Is there a public record of the trial results?

You can check the FDA’s Orange Book-it lists drugs and their approval status. But it’s not user-friendly. If you’re unsure, ask your pharmacist or request a copy of the FDA’s official determination notice.

And if you’re on a drug that’s been flagged? Don’t panic. But don’t assume it’s safe either. Talk to your doctor. Ask if there’s a better option. And don’t be afraid to push for transparency.

The Bigger Picture: Safety, Not Speed

The pharmaceutical industry argues that fast approvals save lives. And sometimes, they do. But we can’t trade safety for speed. The real innovation isn’t in getting drugs to market faster-it’s in knowing which ones actually work.

The 2023 reforms are the strongest signal yet that the FDA is starting to take this seriously. But the test isn’t in the law. It’s in the action.

Will the agency move quickly when the next Makena comes along? Will it stop waiting for paperwork and start acting on data? Will it protect patients before they’re harmed-or only after?

The answer will tell us whether this change was just a policy update-or a true turning point.